Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GUCY1B2 | O75343 | 1/20 | 0.33 |
| ▸ | GUCY1A2 | P33402 | 1/20 | 0.33 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.33 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | MAT2A | P31153 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL248470 | 0.86 | TRPV1 (0.38) | KMT2AOGFRL1OPRM1OPRK1PIK3CD | |
| SCHEMBL248998 | 0.86 | TRPV1 (0.38) | KMT2AOGFRL1OPRM1OPRK1PIK3CD | |
| SCHEMBL248471 | 0.86 | TRPV1 (0.38) | KMT2AOGFRL1OPRM1OPRK1PIK3CD | |
| SCHEMBL14840455 | 0.78 | GPR6 (0.30) | — | |
| SCHEMBL3413292 | 0.78 | CRHR1 (0.45) | — | |
| SCHEMBL2713325 | 0.78 | SMO (0.37) | MAPTSMN1; SMN2 | |
| SCHEMBL247916 | 0.78 | CRHR1 (0.45) | — | |
| SCHEMBL2123656 | 0.76 | PIK3CA (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL2732510 | 0.75 | — | — | |
| SCHEMBL2732511 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2445886-B1 | 4-AMINOQUINOLINE DERIVATIVES AS PI3K INHIBITORS | AMGEN INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-8940724-B2 | Quinoline derivitives and their uses | AMGEN INC. (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2588471-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | Amgen Inc. (US) | 2013-05-08 | — | — | EP | disclosed |
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2013-04-11 | — | — | US | disclosed |
| EP-2445886-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| WO-2012003283-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF PI3K ACTIVITY | AMGEN INC. (US) | 2012-01-05 | — | — | WO | disclosed |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-30 | — | — | US | disclosed |
| WO-2010151791-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090323-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KMT2A 679/4885MAPT 3420/4885MAPK1 1023/4885 |
| US-20100331293-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | KMT2A 880/4885MAPT 3291/4885MAPK1 1029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.